Blog

Rituximab after autologous stem cell transplantation in mantle cell lymphoma patients prolongs survival – 2 Minute Medicine


2 Minute Medicine

Rituximab after autologous stem cell transplantation in mantle cell lymphoma patients prolongs survival
2 Minute Medicine
1. Patients with mantle cell lymphoma treated with autologous stem cell transplantation experienced greater overall, event-free, and progression-free survival when treated with rituximab maintenance therapy compared to patients not receiving
Adding Drug to Standard Care May Prolong Lymphoma SurvivalU.S. News & World Report



all 2 news articles »

2017-09-28 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.